enGene Therapeutics Inc. income statement ENGN

Annual Quarterly

It recorded a net loss of $32.5 million. Diluted earnings per share were -$0.47.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.

TTM
Jul 31, 2026
Q3 FY2026
Jul 31, 2026
Q2 FY2026
Apr 30, 2026
Q1 FY2026
Jan 31, 2026
Q4 FY2025
Oct 31, 2025
Q3 FY2025
Jul 31, 2025
Q2 FY2025
Apr 30, 2025
Q1 FY2025
Jan 31, 2025
Q4 FY2024
Oct 31, 2024
Research and development
96
+30.0%
20
-11.0%
22
+9.8%
22
+11.4%
32
+181.4%
23
+95.5%
20
+105.1%
20
+254.3%
11
Selling, general and administrative
40
+49.0%
14
+88.9%
10
+41.3%
9
+34.5%
8
+25.5%
7
+41.5%
7
-7.2%
7
+29.3%
6
Operating income
-137
-35.1%
-34
-13.6%
-32
-17.9%
-31
-17.2%
-39
-126.2%
-30
-78.7%
-27
-56.7%
-27
-147.0%
-17
Interest income
10
-6.6%
2
+7.5%
3
+7.0%
3
+0.4%
2
-34.7%
2
-33.9%
2
-16.6%
3
+166.3%
3
Interest expense
3
+2.3%
1
+11.2%
1
+1.5%
1
-2.7%
1
-0.8%
1
+0.9%
1
1
1
Other non-operating income (expense)
-0
+20.5%
-0
+83.9%
-0
+13.7%
-0
-335.1%
-0
-30.1%
-0
-495.7%
-0
-325.3%
0
+157.8%
-0
Pretax income
-131
-38.9%
-33
-13.0%
-30
-18.2%
-30
-21.0%
-38
-151.2%
-29
-102.8%
-26
-70.9%
-25
-129.0%
-15
Income tax
-0
-196.3%
0
-100.0%
0
-100.0%
0
-100.0%
-0
-2715.8%
0
+924.1%
0
+1042.9%
0
+160.0%
0
Net income
-130
-37.6%
-33
-12.1%
-30
-17.1%
-30
-20.9%
-38
-147.6%
-29
-104.9%
-26
-72.3%
-25
-129.8%
-15
Basic EPS
-2.02
-5.3%
-0.47
+17.5%
-0.43
+15.7%
0.44
-8.3%
-0.74
-113.8%
-0.57
-278.1%
-0.51
-234.2%
0.48
+4.3%
-0.34
Diluted EPS
-2.02
-5.3%
-0.47
+17.5%
-0.43
+15.7%
0.44
-8.3%
-0.74
-113.8%
-0.57
-278.1%
-0.51
-234.2%
0.48
+4.3%
-0.34
Weighted average shares, basic
64
+30.6%
70
+36.5%
70
+36.7%
67
+31.9%
51
+15.8%
51
+15.7%
51
+29.3%
51
+119.7%
44
Weighted average shares, diluted
64
+30.6%
70
+36.5%
70
+36.7%
67
+31.9%
51
+15.8%
51
+15.7%
51
+29.3%
51
+119.7%
44
Other measures
Depreciation and amortization
1
+75.0%
0
+0.0%
0
+100.0%
0
+85.3%
0
+100.0%
0
+0.0%
0
+0.0%
0
+27.5%
0
EBITDA
-136
-35.0%
-34
-13.6%
-32
-17.6%
-31
-16.9%
-39
-126.3%
-30
-79.2%
-27
-57.0%
-27
-147.9%
-17
Interest coverage
-44.51x
-40.35x
-42.91x
-42.60x
-52.64x
-39.51x
-36.95x
-35.39x
-23.09x
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
ENGN (Nasdaq), ENGNW (Nasdaq)
Fiscal year ends
October 31
Incorporated in
Canada (Federal Level)
Headquarters
Saint-Laurent
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1980845
Former names
enGene Holdings Inc. (until Mar 9, 2026)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.